Infusion fluids contain harmful glucose degradation products

[1]  Mark E. Williams.  New Potential Agents in Treating Diabetic Kidney Disease , 2012, Drugs.

[2]  M. Andrassy,et al.  AGE–modified albumin containing infusion solutions boosts septicaemia and inflammation in experimental peritonitis , 2009, Journal of leukocyte biology.

[3]  Johan Groeneveld,et al.  A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study , 2009, Intensive Care Medicine.

[4]  Stephane Heritier,et al.  Intensive versus conventional glucose control in critically ill patients. , 2009, The New England journal of medicine.

[5]  E. Trikka-Graphakos,et al.  Diabetes mellitus is an independent risk factor for ICU-acquired bloodstream infections , 2009, Intensive Care Medicine.

[6]  J. Teixeira,et al.  Genotoxic damage in pathology anatomy laboratory workers exposed to formaldehyde. , 2008, Toxicology.

[7]  T. L. Archuleta,et al.  Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant alpha-lipoic acid on insulin resistance in the obese Zucker rat. , 2008, Metabolism: clinical and experimental.

[8]  A. Pesenti,et al.  Tight glycemic control does not affect asymmetric-dimethylarginine in septic patients , 2008, Intensive Care Medicine.

[9]  J. Jönsson,et al.  3,4-DGE in Peritoneal Dialysis Fluids Cannot be Found in Plasma after Infusion into the Peritoneal Cavity , 2008, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[10]  B. Hudson,et al.  Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine. , 2008, Biochemistry.

[11]  T. Niwa,et al.  Pyridoxal phosphate prevents progression of diabetic nephropathy. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  R. Silber,et al.  Advanced glycation endproducts: A biomarker for age as an outcome predictor after cardiac surgery? , 2007, Experimental Gerontology.

[13]  F. Schaefer,et al.  Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  R. Saracho,et al.  Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  J. Carrero,et al.  Risk Factors for Cardiovascular Disease in Patients Undergoing Peritoneal Dialysis , 2007, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[16]  L. Berstein,et al.  Glucose-induced effects and joker function of glucose: endocrine or genotoxic prevalence? , 2006, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[17]  Yeong-Hoon Kim,et al.  Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  J. Jönsson,et al.  How to Avoid Glucose Degradation Products in Peritoneal Dialysis Fluids , 2006, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[19]  Yu-His Kuo,et al.  Ras modulation of superoxide activates ERK-dependent fibronectin expression in diabetes-induced renal injuries. , 2006, Kidney international.

[20]  G. Bakris,et al.  Cardiometabolic syndrome and chronic kidney disease: what is the link? , 2006, Journal of the cardiometabolic syndrome.

[21]  J. Jönsson,et al.  Take Care in how you Store Your PD Fluids: Actual Temperature Determines the Balance between Reactive and Non-Reactive GDPs , 2005, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[22]  A. Ortiz,et al.  3,4-di-deoxyglucosone-3-ene promotes leukocyte apoptosis. , 2005, Kidney international.

[23]  A. Sanz,et al.  3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. , 2005, Diabetes.

[24]  A. Dawnay,et al.  Advanced Glycation End Product Free Adducts Are Cleared by Dialysis , 2005, Annals of the New York Academy of Sciences.

[25]  Anne Dawnay,et al.  Profound mishandling of protein glycation degradation products in uremia and dialysis. , 2005, Journal of the American Society of Nephrology : JASN.

[26]  K. Craig,et al.  The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. , 2004, Kidney international.

[27]  T. Brown,et al.  Modulation of in vivo 3-deoxyglucosone levels. , 2003, Biochemical Society transactions.

[28]  Y. Ohta,et al.  Glucose degradation products (GDP) retard remesothelialization independently of D-glucose concentration. , 2003, Kidney international.

[29]  J. Baynes,et al.  The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. , 2003, Kidney international.

[30]  M. Kasuga,et al.  Relation between serum 3-deoxyglucosone and development of diabetic microangiopathy. , 2003, Diabetes care.

[31]  G. Stein,et al.  Serum levels of total homocysteine, homocysteine metabolites and of advanced glycation end-products (AGEs) in patients after renal transplantation. , 2003, Clinical nephrology.

[32]  C. Wanner,et al.  Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? , 2003, Kidney international.

[33]  A. Wieslander,et al.  3,4-Dideoxyglucosone-3-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis. , 2002, Kidney international.

[34]  A. Christensson,et al.  Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. , 2001, Kidney international.

[35]  T. Henle,et al.  3-Deoxyglucosone, a Promoter of Advanced Glycation end Products in Fluids for Peritoneal Dialysis , 1998, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[36]  G. Williams,et al.  Formaldehyde mechanistic data and risk assessment: endogenous protection from DNA adduct formation. , 1996, Pharmacology & therapeutics.

[37]  A. Wieslander,et al.  Are Aldehydes in Heat-Sterllized Peritoneal Dialysis Fluids Toxic in Vitro? , 1995, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[38]  A. Wieslander,et al.  Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929. , 1991, Kidney international.

[39]  V. Feron,et al.  Cytotoxic and adaptive effects in rat nasal epithelium after 3-day and 13-week exposure to low concentrations of formaldehyde vapour. , 1988, Toxicology.

[40]  S J Northup,et al.  A review of 5-hydroxymethylfurfural (HMF) in parenteral solutions. , 1984, Fundamental and applied toxicology : official journal of the Society of Toxicology.